By InvitationNot Applicable

Biomarkers in a Candian Memory Clinic

Canada100 participantsStarted 2024-06-11

Plain-language summary

This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. This study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (DMT)) to triage patients towards biological staging of disease with biomarker testing.

Who can participate

Age range55 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Individual with MCI (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA)
✓. MoCA score must be 18 to 28 inclusive
✓. Age 55 to 80 years inclusive
✓. Has a study partner that is willing to participate as a source of information and has approximately weekly contact with the subject (contact can be in-person, via telephone or electronic communication). The study partner must have sufficient contact such that the investigator feels the study partner can provide meaningful information about the subject's daily function.
✓. Group A - must have a clinical memory assessment appointment scheduled at Parkwood Institute within 18 months of baseline
✓. Group B - must have had a clinical memory assessment appointment at Parkwood Institute within 18 months of baseline

What they're measuring

Determine the feasibility of integrating a CSF biomarker into diagnostic decision making for AD.

Timeframe: through study completion, approximately 1 year

Trial details

NCT IDNCT06843109

SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09

View on ClinicalTrials.gov More Alzheimer's Disease (AD) trials